CN110664920B - Medicine for resisting aquatic pathogenic stenotrophomonas maltophilia and preparation method thereof - Google Patents
Medicine for resisting aquatic pathogenic stenotrophomonas maltophilia and preparation method thereof Download PDFInfo
- Publication number
- CN110664920B CN110664920B CN201810714829.6A CN201810714829A CN110664920B CN 110664920 B CN110664920 B CN 110664920B CN 201810714829 A CN201810714829 A CN 201810714829A CN 110664920 B CN110664920 B CN 110664920B
- Authority
- CN
- China
- Prior art keywords
- extract
- areca
- concentration
- nut
- stenotrophomonas maltophilia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/739—Sanguisorba (burnet)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/889—Arecaceae, Palmae or Palmaceae (Palm family), e.g. date or coconut palm or palmetto
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Abstract
The invention relates to a medicament for resisting aquatic pathogenic stenotrophomonas maltophilia, which is a Chinese and western medicine compound preparation and contains a Chinese medicinal extract, namely a garden burnet extract, a areca-nut extract and western medicines, namely gentamicin sulfate and didecyldimethylammonium chloride, not only can scientifically combine the advantages of high-efficiency and quick-acting antibacterial effects of the western medicines with the characteristics of difficult generation of drug resistance and small toxic and side effects of the Chinese medicinal preparation, but also more importantly, the inventor unexpectedly discovers that when the garden burnet extract and the areca-nut extract with specific concentrations, the gentamicin sulfate and the didecyldimethylammonium chloride are adopted, the four compounds can synergistically promote and more effectively resist the aquatic pathogenic stenotrophomonas maltophilia, so that the use amount of the medicament, particularly the western medicines, can be reduced, the cost is reduced, and the toxic and side effects of the medicament use on a culture environment are favorably, improving the health level of aquatic animals.
Description
Technical Field
The invention relates to a medicament for resisting aquatic pathogenic stenotrophomonas maltophilia and a preparation method thereof, belonging to the technical field of aquaculture medicaments.
Background
The stenotrophomonas maltophilia is a conditioned pathogen widely existing in aquaculture environments, and due to the fact that the stenotrophomonas maltophilia has multiple inherent drug resistance mechanisms, the stenotrophomonas maltophilia has strong drug resistance to most of antibacterial drugs and is only sensitive to drugs such as sulfamethoxazole and cefoperazone, the control of the pathogenic stenotrophomonas maltophilia of the aquatic products is quite difficult (the research on the natural and acquired drug resistance mechanisms of the stenotrophomonas maltophilia advances [ J ]. China J.J.antibiotics 2011, 36 (9): 654-658; the risk factors and the drug resistance analysis of the stenotrophomonas maltophilia [ J ]. China J.J.infections and chemotherapy, 2014, 14 (2): 112-115). Therefore, there is a great need to develop a new formulation against pathogenic stenotrophomonas maltophilia to effectively control the pathogenic stenotrophomonas maltophilia of aquatic animals and reduce the incidence of diseases caused by the pathogenic stenotrophomonas maltophilia.
The Chinese and western medicine compound preparation is a new medicine, is a compound preparation formed by combining Chinese medicines and western medicines (trial and review Chinese and western medicine compound preparation [ J ], Chinese veterinary medicine journal, 1999 (02): 49-53), scientifically combines the advantages of high-efficiency and quick-acting antibacterial of the western medicines and the characteristics of difficult drug resistance generation and small toxic and side effects of the Chinese medicine preparation, and has the advantages that the single use of the western medicines and the single use of the Chinese medicines are difficult to compare.
Therefore, the development of a novel preparation for resisting aquatic pathogenic stenotrophomonas maltophilia from the perspective of the compound of western medicines is also a new idea, and the development of a novel preparation for resisting the aquatic pathogenic stenotrophomonas maltophilia scientifically combines the advantages of high-efficiency and quick-acting antibacterial of the western medicines and the characteristics of difficult drug resistance generation and small toxic and side effects of the traditional Chinese medicine preparation together scientifically, more effectively controls the aquatic pathogenic stenotrophomonas maltophilia, and reduces the occurrence rate of aquatic animal diseases caused by the aquatic pathogenic stenotrophomonas maltophilia; on the other hand, the dosage of the medicine, especially western medicine, is reduced, the cost is reduced, the toxic and side effects of the medicine on the culture environment are favorably reduced, and the health level of aquatic animals is improved.
Disclosure of Invention
In order to solve the technical problems, the invention provides a medicament for resisting aquatic pathogenic stenotrophomonas maltophilia on one hand, wherein the medicament is a Chinese and western medicine compound preparation which is an aqueous solution containing sanguisorba extract, areca-nut tablet extract, gentamicin sulfate and didecyldimethyl ammonium chloride, and the concentration of crude drugs contained in the sanguisorba extract is 0.3-0.5 g/ml; the crude drug concentration of the areca-nut tablet extract is 0.08-0.12 g/ml; the concentration of the gentamicin sulfate is 0.3-0.5 g/ml; the concentration of the didecyl dimethyl ammonium chloride is 0.07-0.09 g/ml.
Preferably, the sanguisorba officinalis extract contains crude drug with concentration of 0.4 g/ml; the crude drug concentration of the areca-nut tablet extract is 0.1 g/ml; the concentration of the gentamicin sulfate is 0.4 g/ml; the concentration of the didecyl dimethyl ammonium chloride is 0.08 g/ml.
Preferably, the preparation method comprises the steps of preparing a garden burnet extract, preparing a areca-nut piece extract and mixing the obtained garden burnet extract and areca-nut piece extract with a gentamicin sulfate drug and a didecyl dimethyl ammonium chloride solution.
Preferably, the step of preparing the sanguisorba extract comprises: according to the proportion of adding 8-12g of sanguisorba officinalis into 100ml of water, soaking the sanguisorba officinalis in the water for 20-60 minutes, decocting, wherein the decocting process is to boil the water and then boil the water with slow fire for 20-40 minutes, and filtering out filtrate; decocting for 2-5 times, mixing the filtrates, and concentrating until the concentration of the crude drug in the sanguisorba officinalis extract is 0.8-1.2 g/ml to obtain the sanguisorba officinalis extract; the preparation method of the areca-nut sheet extracting solution comprises the following steps: soaking the areca-nut pieces in water for 20-40 minutes according to the proportion of adding 8-12g of the areca-nut pieces into 100ml of water, decocting, wherein the decocting process is to boil the water and then boil the water for 20-40 minutes, and filtering out filtrate; decocting for 2-5 times, combining filtrates, and concentrating until the crude drug concentration of the extract of the betel nut sheet is 0.8-1.2 g/ml, thereby obtaining the extract of the betel nut sheet.
Preferably, the garden burnet extract and the areca-nut piece extract are mixed and evenly stirred for 0.5 to 1.0 hour at room temperature under the condition of 30 to 50r/min, then the gentamicin sulfate is added, the even stirring is continued for 0.5 to 1.0 hour at room temperature under the condition of 30 to 50r/min, finally, the didecyl dimethyl ammonium chloride solution is added, the even stirring is continued for 0.5 to 1.0 hour at room temperature under the condition of 30 to 50r/min, and the medicine for resisting the aquatic pathogenic stenotrophomonas maltophilia is prepared.
The medicament for resisting the aquatic pathogenic stenotrophomonas maltophilia is a Chinese and western medicine compound preparation, is an aqueous solution containing traditional Chinese medicine extracts (sanguisorba extract and areca-nut extract) and western medicines (gentamicin sulfate and didecyldimethylammonium chloride), not only can scientifically combine the advantages of high-efficiency and quick-acting antibacterial of the western medicines with the characteristics that the traditional Chinese medicine preparation is not easy to generate drug resistance and has small toxic and side effects, but also more importantly, the inventor unexpectedly discovers that when the sanguisorba extract and the areca-nut extract with specific concentrations are adopted, the gentamicin sulfate and the didecyldimethylammonium chloride, the four compounds can be synergistically promoted to more effectively resist the aquatic pathogenic stenotrophomonas maltophilia, so that the using amount of the medicaments, particularly the western medicines, can be reduced, the cost is reduced, and the toxic and side effects of the medicament use on the culture environment are favorably reduced, improving the health level of aquatic animals.
Detailed Description
The present invention will be further described with reference to the following examples, but the present invention is not limited to these specific embodiments.
The explanation about the terms is as follows:
the term "crude drug-containing concentration" refers to the concentration obtained by dividing the weight of all natural unprocessed or simply processed Chinese medicinal materials (plants, animals and minerals) in a prescription by the volume of a decoction.
In a specific embodiment of the invention, the medicine for resisting the aquatic pathogenic stenotrophomonas maltophilia is provided, wherein the medicine is a Chinese and western medicine compound preparation which is an aqueous solution containing sanguisorba extract, areca-nut tablet extract, gentamicin sulfate and didecyldimethyl ammonium chloride, and the concentration of the crude drug contained in the sanguisorba extract is 0.3-0.5 g/ml; the crude drug concentration of the areca-nut tablet extract is 0.08-0.12 g/ml; the concentration of the gentamicin sulfate is 0.3-0.5 g/ml; the concentration of the didecyl dimethyl ammonium chloride is 0.07-0.09 g/ml.
In a preferred embodiment of the present invention, the sanguisorba officinalis extract has a crude drug concentration of 0.4 g/ml; the crude drug concentration of the areca-nut tablet extract is 0.1 g/ml; the concentration of the gentamicin sulfate is 0.4 g/ml; the concentration of the didecyl dimethyl ammonium chloride is 0.08 g/ml.
Regarding the research and development of the medicament for resisting the pathogenic aquatic pathogenic stenotrophomonas maltophilia, the inventor screens out a plurality of traditional Chinese medicine candidates with better effects including sanguisorba extract and areca-nut extract from a large number of traditional Chinese medicine candidates, and screens out a plurality of western medicine candidates with better effects including gentamicin sulfate and didecyl dimethyl ammonium chloride solution from a large number of western medicine candidates.
From the composition and mechanism of action of these substances, the inventors can conclude that: saponin and chrysophanol in the garden burnet extract, and various active substances such as arecoline and phenol in the areca-nut sheet extract can inhibit the growth of stenotrophomonas maltophilia, gentamicin sulfate can inhibit the synthesis of bacterial protein by combining with a bacterial ribosome 30s subunit, didecyl dimethyl ammonium chloride can change the permeability of a bacterial cell serous membrane, so that the bacterial substance is caused to permeate outwards to cause the bacterial death; however, the western medicines gentamicin sulfate and didecyl dimethyl ammonium chloride have large toxic and side effects when used, have more drug residues, have large environmental pollution, and easily cause aquatic pathogenic stenotrophomonas maltophilia to generate drug resistance to cause sensitivity reduction, especially the didecyl dimethyl ammonium chloride is easily influenced by organic matters in a water environment to cause antibacterial effect reduction.
The inventor carries out any compound combination of the traditional Chinese medicine and western medicine candidates, and makes a large number of combination experiments, and unexpectedly discovers that when the traditional Chinese medicine and western medicine compound preparation prepared by compounding the sanguisorba extract and the areca catechu extract with specific concentrations with gentamicin sulfate and didecyl dimethyl ammonium chloride solution is adopted, the four compound preparations can be synergistically promoted to more effectively resist aquatic pathogenic stenotrophomonas maltophilia. After the inventor obtains the unexpected finding, the inventor further conducts the research of the drug mechanism, and speculates that according to the research result: the active ingredients in the extracts of garden burnet and areca-nut are utilized to enable the effective ingredients of didecyl dimethyl ammonium chloride to be more easily gathered on the surface of cells, the integrity of the cell walls and cell membranes of aquatic pathogenic stenotrophomonas maltophilia thallus is damaged, gentamicin sulfate is more favorably enabled to enter the thallus to be firmly combined with specific proteins on bacterial ribosomal subunits, the function of the ribosomal is interfered, and finally the bacteria are killed; therefore, the combination of the Chinese medicine and the western medicine reduces the using amount of the western medicine, reduces the pollution to the environment and the toxic and side effect, and is favorable for avoiding the generation of drug resistance of the aquatic pathogenic stenotrophomonas maltophilia to the medicine.
Example 1
The medicine is a Chinese and western medicine compound preparation, and is an aqueous solution containing sanguisorba extract, areca-nut tablet extract, gentamicin sulfate and didecyl dimethyl ammonium chloride, wherein the crude drug concentration of the sanguisorba extract is 0.4g/ml, the crude drug concentration of the areca-nut tablet extract is 0.1g/ml, the concentration of gentamicin sulfate is 0.4g/ml, and the concentration of didecyl dimethyl ammonium chloride is 0.08 g/ml.
The preparation method comprises the following steps:
firstly, preparing a garden burnet extract and a betel nut piece extract respectively, and then mixing the obtained garden burnet extract and the obtained betel nut piece extract with a gentamicin sulfate solution and a didecyl dimethyl ammonium chloride solution, which is as follows.
The preparation method of the garden burnet extract comprises the following steps: soaking sanguisorba officinalis in water for 30 minutes according to the proportion that 10g of sanguisorba officinalis is added into every 100ml of water, decocting, wherein the decocting process is to boil the water and then boil the water for 30 minutes with slow fire, and filtering out filtrate; decocting for 3 times, mixing filtrates, and concentrating until the concentration of radix Sangusorbae extract containing crude drug is 1g/ml to obtain radix Sangusorbae extractive solution containing crude drug at 1 g/ml;
preparing an extract of the betel nut pieces: soaking the areca-nut pieces in water for 30 minutes according to the proportion of adding 10g of the areca-nut pieces into 100ml of water, decocting, wherein the decocting process is to boil the water and then boil the water for 30 minutes by slow fire, and filtering out filtrate; decocting for 3 times, mixing filtrates, and concentrating to obtain extract containing crude drug at 1 g/ml;
mixing the obtained 40ml of sanguisorba extract and 10ml of areca-nut extract, uniformly stirring for 0.5-1.0 hour at room temperature under the condition of 30-50r/min, then adding 40g of gentamicin sulfate (specifically, 40g of gentamicin sulfate powder is added in the embodiment), continuously and uniformly stirring for 0.5-1.0 hour at room temperature under the condition of 30-50r/min, then adding 10ml of didecyl dimethyl ammonium chloride solution with the concentration of 0.8g/ml, continuously and uniformly stirring for 0.5-1.0 hour at room temperature under the condition of 30-50r/min, finally adding water for quantifying to 100ml, and obtaining 100ml of the water-resistant pathogenic stenotrophomonas maltophilia.
Effect data
In order to prove the effect of the medicament for resisting aquatic pathogenic stenotrophomonas maltophilia in example 1, the inventor selects three conventional aquatic pathogenic stenotrophomonas maltophilia, namely Pelteobagrus fulvidraco pathogenic stenotrophomonas WY1, leiocassis pathogenic stenotrophomonas maltophilia HS01 and carp pathogenic stenotrophomonas maltophilia LS02, which are provided by the aquatic animal pathogen library of Shanghai ocean university.
Firstly, bacterial suspensions of the three stenotrophomonas maltophilia are prepared: respectively selecting the pelteobagrus fulvidraco pathogenic stenotrophomonas WY1, the leiocassis pathogenic stenotrophomonas HS01 and the carp pathogenic stenotrophomonas LS02 from a solid inclined plane, streaking and inoculating a nutrient agar plate, placing the plate in a constant-temperature incubator at 28 ℃ and culturing for 24 hours; selecting single colony in nutrient broth liquid culture medium, shake culturing at 28 deg.C for 18 hr at 200r/min, and adjusting bacteria liquid concentration to 10 with sterile normal saline7cfu/mL, stored in a refrigerator at 4 ℃ for later use.
Control group 1: extracting solution of garden burnet;
control group 2: extracting solution of areca-nut pieces;
control group 3: gentamicin sulfate drug (drug powder);
control group 4: aqueous solution of didecyl dimethyl ammonium chloride;
control group 5: cefotaxime sodium drug (drug powder);
wherein the control group 5 is conventional antibacterial western medicine; in addition, blank sterile nutrient broth of the same culture conditions was used as a negative control;
the minimum inhibitory concentrations of the drugs of the control groups 1 to 5 and example 1 against the three conventional pathogenic stenotrophomonas maltophilia in aquatic products were measured, and the mass concentration (or crude drug-containing concentration) of the drug that grew aseptically and was diluted to the maximum was taken as the minimum inhibitory concentration (mg/L) of the drug against the pathogenic stenotrophomonas maltophilia in aquatic products.
See table 1 below for results;
TABLE 1
As can be seen from the results in table 1, the minimum inhibitory concentration of the drug against pathogenic aquatic mallophilic stenotrophomonas of example 1 of the present invention is lower than that of the conventional western drug (cefotaxime sodium or gentamicin sulfate), which proves that the drug of example 1 of the present invention has excellent effect against pathogenic aquatic mallophilic stenotrophomonas;
in addition, the minimum inhibitory concentration of the drug for resisting the pathogenic aquatic stenotrophomonas maltophilia in the embodiment 1 of the invention is not only lower than that of a single western medicine medicament (didecyl dimethyl ammonium chloride solution or gentamicin sulfate drug) but also far lower than that of a single traditional Chinese medicine medicament (garden burnet and areca-nut piece extracting solution), and the effect of synergistic promotion is proved to be achieved among the four components in the drug in the embodiment 1 of the invention; taking the data of the pathogenic stenotrophomonas maltophilia WY1 of the yellow catfish as an example, the synergistic action index (FIC index) among the four components in the medicine of the embodiment 1 of the invention is calculated by the following formula:
FIC index-MIC (example 1 drug-Sanguisorbae officinalis combined)/MIC (Sanguisorbae officinalis used alone) + MIC (example 1 drug-Areca seed combined)/MIC (Areca seed used alone) + MIC (example 1 drug-didecyldimethylammonium chloride combined)/MIC (didecyldimethylammonium chloride used alone) + MIC (example 1 drug-Gentamicin sulfate combined)/MIC (Gentamicin sulfate used alone)
The FIC value 0.219848 (less than 0.5) is obtained by calculation, which shows that the compound of the sanguisorba extract, the areca-nut extract, the gentamicin sulfate and the didecyl dimethyl ammonium chloride solution has a synergistic promotion effect on the aspect of resisting aquatic pathogenic stenotrophomonas maltophilia.
In conclusion, the medicament for resisting the aquatic pathogenic stenotrophomonas maltophilia is a Chinese and western medicine compound preparation, is an aqueous solution containing traditional Chinese medicine extracts (sanguisorba extract and areca-nut extract) and western medicines (gentamicin sulfate and didecyldimethylammonium chloride), can scientifically combine the advantages of high-efficiency and quick-acting antibacterial of the western medicines and the characteristics of difficult drug resistance generation and small toxic and side effects of the traditional Chinese medicine preparation, and more importantly, the inventor surprisingly discovers that when the sanguisorba extract, the areca-nut extract, the gentamicin sulfate and the didecyldimethylammonium chloride with specific concentrations are adopted, the four compounds can be synergistically promoted to resist the aquatic pathogenic stenotrophomonas maltophilia more effectively, so that the use amount of the medicaments, particularly the western medicines, can be reduced, the cost is reduced, and the toxic and side effects of the medicament use on the culture environment can be favorably reduced, improving the health level of aquatic animals.
It should be understood that although the present description refers to embodiments, not every embodiment contains only a single technical solution, and such description is for clarity only, and those skilled in the art should make the description as a whole, and the technical solutions in the embodiments can also be combined appropriately to form other embodiments understood by those skilled in the art.
The above-listed detailed description is only a specific description of a possible embodiment of the present invention, and they are not intended to limit the scope of the present invention, and equivalent embodiments or modifications made without departing from the technical spirit of the present invention should be included in the scope of the present invention.
Claims (5)
1. A medicament against pathogenic aquatic stenotrophomonas maltophilia is characterized in that:
the medicine is a compound preparation of Chinese and western medicines, which is an aqueous solution containing sanguisorba extract, areca-nut tablet extract, gentamicin sulfate and didecyl dimethyl ammonium chloride,
the concentration of the crude drug contained in the sanguisorba extract is 0.3-0.5 g/ml;
the crude drug concentration of the areca-nut sheet extract is 0.08-0.12 g/ml;
the concentration of the gentamicin sulfate is 0.3-0.5 g/ml;
the concentration of the didecyl dimethyl ammonium chloride is 0.07-0.09 g/ml.
2. The medicament of claim 1, which is resistant to pathogenic aquatic stenotrophomonas maltophilia, characterized in that:
the radix Sangusorbae extract contains crude drug with concentration of 0.4 g/ml;
the crude drug concentration of the areca-nut tablet extract is 0.1 g/ml;
the concentration of the gentamicin sulfate is 0.4 g/ml;
the concentration of the didecyl dimethyl ammonium chloride is 0.08 g/ml.
3. The method of claim 1 for preparing a medicament against pathogenic aquatic stenotrophomonas maltophilia, wherein:
the preparation method comprises the steps of preparing a garden burnet extract, preparing a betel nut piece extract and mixing the obtained garden burnet extract and the betel nut piece extract with a gentamicin sulfate drug and a didecyl dimethyl ammonium chloride solution.
4. The method of claim 3, wherein:
the preparation method of the garden burnet extract comprises the following steps: according to the proportion of adding 8-12g of sanguisorba officinalis into 100ml of water, soaking the sanguisorba officinalis in the water for 20-60 minutes, and then decocting, wherein the decocting process is to boil the water and then boil the water with slow fire for 20-40 minutes, and filtering out filtrate; decocting for 2-5 times, mixing the filtrates, and concentrating until the concentration of the crude drug in the sanguisorba officinalis extract is 0.8-1.2 g/ml to obtain the sanguisorba officinalis extract;
the preparation method of the areca-nut sheet extracting solution comprises the following steps: soaking the areca-nut pieces in water for 20-40 minutes according to the proportion of adding 8-12g of the areca-nut pieces into 100ml of water, decocting, wherein the decocting process is to boil the water and then boil the water for 20-40 minutes by slow fire, and filtering out filtrate; decocting for 2-5 times, combining filtrates, and concentrating until the crude drug concentration of the extract of the betel nut sheet is 0.8-1.2 g/ml, thereby obtaining the extract of the betel nut sheet.
5. The method of claim 4, wherein:
mixing the garden burnet extract and the areca-nut piece extract, uniformly stirring for 0.5-1.0 hour at room temperature under the condition of 30-50r/min, then adding gentamycin sulfate, continuously and uniformly stirring for 0.5-1.0 hour at room temperature under the condition of 30-50r/min, finally adding didecyl dimethyl ammonium chloride solution, continuously and uniformly stirring for 0.5-1.0 hour at room temperature under the condition of 30-50r/min, and blending to obtain the medicament for resisting the pathogenic stenotrophomonas maltophilia of the aquatic product according to claim 1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810714829.6A CN110664920B (en) | 2018-07-03 | 2018-07-03 | Medicine for resisting aquatic pathogenic stenotrophomonas maltophilia and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810714829.6A CN110664920B (en) | 2018-07-03 | 2018-07-03 | Medicine for resisting aquatic pathogenic stenotrophomonas maltophilia and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110664920A CN110664920A (en) | 2020-01-10 |
| CN110664920B true CN110664920B (en) | 2021-05-14 |
Family
ID=69065472
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810714829.6A Active CN110664920B (en) | 2018-07-03 | 2018-07-03 | Medicine for resisting aquatic pathogenic stenotrophomonas maltophilia and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110664920B (en) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070258996A1 (en) * | 2005-12-23 | 2007-11-08 | The Sterilex Corporation | Antimicrobial compositions |
| CN102223876A (en) * | 2008-09-26 | 2011-10-19 | 纳米生物公司 | Nanoemulsion therapeutic compositions and methods of using the same |
| CN102670674A (en) * | 2012-06-02 | 2012-09-19 | 大理学院 | Geranium strictipes R. Knuth effective part extract as well as preparation method and drug application |
-
2018
- 2018-07-03 CN CN201810714829.6A patent/CN110664920B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN110664920A (en) | 2020-01-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101856029B (en) | Pesticide combination containing etoxazole and abamectin | |
| CN103503930A (en) | Botanical pesticide composition and application thereof | |
| CN105287790A (en) | Paederia scandens extract and applications thereof | |
| CN109602779B (en) | Traditional Chinese medicine composition and application thereof in preparation of medicine for preventing and treating grouper iridovirus disease | |
| CN115120602A (en) | Antifungal medicine synergist | |
| CN112375708B (en) | Preparation for resisting white spot syndrome virus and Octopus iridovirus 1 and preparation method thereof | |
| CN102948434A (en) | Aquaculture sterilization parasiticide | |
| CN107836465B (en) | Insecticidal composition using fermentation liquor containing metarhizium anisopliae and hydramethylnon as main active ingredients | |
| CN110664920B (en) | Medicine for resisting aquatic pathogenic stenotrophomonas maltophilia and preparation method thereof | |
| CN107439551A (en) | Bactericidal composition containing kasugarnycin and copper rosinate | |
| CN101543506A (en) | Compound antibiotic composition for preventing or treating Streptococcus suis | |
| CN115624578A (en) | Traditional Chinese medicine composition for inhibiting aeromonas hydrophila and application thereof | |
| CN110664901B (en) | Medicine for resisting aquatic pathogenic bacillus mycoides and preparation method thereof | |
| CN115192593A (en) | Application of daunorubicin in treating multiple drug-resistant bacteria infection diseases | |
| CN106619829A (en) | Medicine with resistance to staphylococcus aureus as well as preparation method and application of medicine | |
| CN110664881A (en) | Medicine for resisting aquatic pathogenic Citrobacter freundii and preparation method thereof | |
| CN102823611A (en) | Compound bactericide for preventing and controlling strawberry anthracnose and application thereof | |
| CN105309441B (en) | Composition pesticide containing nitrile pyrrole mite ester and its purposes in prevention and treatment harmful mite | |
| CN104255751A (en) | Mite-killing composition containing etoxazole and vermectin | |
| CN114129635B (en) | Antibacterial composition containing capsicum extract and its application | |
| CN114209732B (en) | Medicine for preventing and treating nocardiosis and application thereof | |
| CN115804807B (en) | Traditional Chinese medicine compound composition for preventing and treating mycoplasma ovipneumoniae and preparation method and application thereof | |
| CN115093974B (en) | Application of cladosporium cucumerinum and fermentation product thereof in preparation of antibacterial drugs | |
| CN111700891B (en) | Pharmaceutical composition for resisting pathogenic bacteria of acinetobacter venenatus | |
| CN107875154A (en) | Composition containing Piperacillin, its pharmaceutical preparation and its application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |